Mereo BioPharma Group plc (MAH0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mereo BioPharma Group plc (MAH0) has a cash flow conversion efficiency ratio of -0.157x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.31 Million ≈ $-8.54 Million USD) by net assets (€46.60 Million ≈ $54.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mereo BioPharma Group plc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Mereo BioPharma Group plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Mereo BioPharma Group plc total liabilities for a breakdown of total debt and financial obligations.
Mereo BioPharma Group plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mereo BioPharma Group plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MoneyHero Limited Class A Ordinary Shares
NASDAQ:MNY
|
-0.007x |
|
JP Morgan Global Growth & Income PLC
LSE:JGGI
|
0.004x |
|
S H L Telemedicine Ltd
SW:SHLTN
|
-0.059x |
|
Manomay Tex India Limited
NSE:MANOMAY
|
0.040x |
|
Jeil Technos Co.Ltd
KQ:038010
|
-0.022x |
|
Beammwave AB B
ST:BEAMMW-B
|
-0.048x |
|
Sumi Indo Kabel Tbk
JK:IKBI
|
0.195x |
|
Lohakit Metal Public Company Limited
BK:LHK
|
0.043x |
Annual Cash Flow Conversion Efficiency for Mereo BioPharma Group plc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Mereo BioPharma Group plc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Mereo BioPharma Group plc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €60.97 Million ≈ $71.28 Million |
€-32.83 Million ≈ $-38.39 Million |
-0.539x | -28.79% |
| 2023-12-31 | €50.54 Million ≈ $59.08 Million |
€-21.13 Million ≈ $-24.71 Million |
-0.418x | +33.36% |
| 2022-12-31 | €61.87 Million ≈ $72.33 Million |
€-38.82 Million ≈ $-45.38 Million |
-0.627x | -953.98% |
| 2021-12-31 | €88.00 Million ≈ $102.88 Million |
€-5.24 Million ≈ $-6.12 Million |
-0.060x | -103.14% |
| 2020-12-31 | €-14.97 Million ≈ $-17.50 Million |
€-28.34 Million ≈ $-33.13 Million |
1.893x | +265.92% |
| 2019-12-31 | €40.26 Million ≈ $47.06 Million |
€-45.93 Million ≈ $-53.70 Million |
-1.141x | -61.59% |
| 2018-12-31 | €32.77 Million ≈ $38.31 Million |
€-23.14 Million ≈ $-27.05 Million |
-0.706x | -37.23% |
| 2017-12-31 | €62.48 Million ≈ $73.05 Million |
€-32.15 Million ≈ $-37.59 Million |
-0.515x | -37.48% |
| 2016-12-31 | €79.26 Million ≈ $92.66 Million |
€-29.66 Million ≈ $-34.68 Million |
-0.374x | -- |
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more